Aptose Biosciences

Aptose Biosciences is a science-driven biotech focused on developing first-in-class, oral small molecule kinase inhibitors for life-threatening hematologic cancers. Its strategy centers on rationally designed, mutation-agnostic compounds that target multiple key oncogenic pathways to address resistance and broaden efficacy. The company's most advanced assets, tuspetinib for AML and luxeptinib for B-cell malignancies and AML, are in Phase 1/2 development, with promising clinical data generating interest, culminating in a definitive agreement for acquisition by Hanmi Pharmaceutical.

Rational design of oral, mutation-agnostic small molecule kinase inhibitors with deliberate multi-kinase profiles to overcome resistance mechanisms in cancer.

In AML, tuspetinib competes with FLT3 and BCL-2 inhibitors but differentiates via its multi-kinase profile. In B-cell cancers, luxeptinib faces established BTK inhibitors but targets resistance mutations. Its dual myeloid/lymphoid activity is a unique differentiator.